We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+2.96%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.85B
AUM Growth
+$405M
(+28%)
Cap. Flow
+$418M
Cap. Flow
% of AUM
22.56%
Top 10 Holdings %
Top 10 Hldgs %
65.27%
Holding
41
New
6
Increased
10
Reduced
6
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total Stock Market ETF
VTI
|
+$269M |
| 2 |
TEM
Tempus AI
TEM
|
+$125M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$111M |
| 4 |
MRUS
Merus
MRUS
|
+$32.7M |
| 5 |
Celldex Therapeutics
CLDX
|
+$32.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewell Personal Care
EPC
|
+$116M |
| 2 |
ASML
ASML
|
+$47.3M |
| 3 |
Insmed
INSM
|
+$20.9M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$18.4M |
| 5 |
Inspire Medical Systems
INSP
|
+$14.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.05% |
| 2 | Technology | 16.21% |
| 3 | Financials | 9.98% |
| 4 | Communication Services | 2.26% |
| 5 | Consumer Discretionary | 1.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vanguard Total Stock Market ETF
VTI
$656B
| $278M | 14.98% |
+1,038,550
| New | +$269M |
|
2
Brookfield
BN
$104B
| $161M | 8.69% |
5,820,345
| – | – |
|
|
TEM
3
Tempus AI
TEM
$7.72B
| $143M | 7.69% |
+4,074,419
| New | +$125M |
|
|
4
ASML
ASML
$608B
| $136M | 7.35% |
133,336
-49,200
| -27% | -$47.3M |
|
5
Salesforce
CRM
$149B
| $123M | 6.66% |
480,160
| – | – |
|
|
6
Edgewise Therapeutics
EWTX
$4.34B
| $114M | 6.16% |
+6,344,430
| New | +$111M |
|
7
Corcept Therapeutics
CORT
$10.1B
| $78.3M | 4.22% |
2,411,362
| – | – |
|
8
Vaxcyte
PCVX
$7.88B
| $71.7M | 3.87% |
950,000
+105,000
| +12% | +$7.15M |
|
|
9
Insmed
INSM
$22.6B
| $53.6M | 2.89% |
800,000
-539,304
| -40% | -$20.9M |
|
10
Mirum Pharmaceuticals
MIRM
$6.84B
| $51.3M | 2.76% |
1,500,000
| – | – |
|
11
Crinetics Pharmaceuticals
CRNX
$8.88B
| $44.8M | 2.41% |
1,000,000
-98,600
| -9% | -$4.55M |
|
12
Cable One
CABO
$249M
| $41.9M | 2.26% |
118,403
| – | – |
|
13
BioMarin Pharmaceuticals
BMRN
$12B
| $40.3M | 2.17% |
490,000
+40,000
| +9% | +$3.33M |
|
|
MRUS
14
DELISTED
Merus
MRUS
| $39.9M | 2.15% |
+675,000
| New | +$32.7M |
|
15
Apple
AAPL
$4.99T
| $38.5M | 2.08% |
182,960
| – | – |
|
16
Alibaba
BABA
$276B
| $36.1M | 1.94% |
500,827
| – | – |
|
17
Pharvaris
PHVS
$2.35B
| $32.4M | 1.75% |
1,725,000
+556,970
| +48% | +$11.3M |
|
|
18
Celldex Therapeutics
CLDX
$2.79B
| $31.5M | 1.7% |
+850,000
| New | +$32.1M |
|
19
4D Molecular Therapeutics
FDMT
$515M
| $29.4M | 1.58% |
1,400,000
| – | – |
|
20
LanzaTech
LNZA
$60.4M
| $29.3M | 1.58% |
158,148
| – | – |
|
21
Alnylam Pharmaceuticals
ALNY
$38.5B
| $28.8M | 1.55% |
118,383
| – | – |
|
22
ArriVent BioPharma
AVBP
$1.4B
| $27.8M | 1.5% |
1,500,000
+422,860
| +39% | +$7.54M |
|
23
Viridian Therapeutics
VRDN
$2.15B
| $26M | 1.4% |
2,000,000
+900,000
| +82% | +$12.5M |
|
|
CRGX
24
DELISTED
CARGO Therapeutics
CRGX
| $25.4M | 1.37% |
1,544,000
+294,000
| +24% | +$5.59M |
|
|
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
| $24.8M | 1.34% |
2,500,000
| – | – |
|
Similar funds
HCA
GX
MP
FLII
CA
IC
WTA
CCA
Novo Holdings A/S's Q2 2024 Portfolio in Review
As of Q2 2024, Novo Holdings A/S held 41 positions worth $1.85B, up 28% from $1.45B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Novo Holdings A/S deployed $418M of net new capital in Q2 2024, opening 6 new positions and adding to 10 existing holdings. Its largest new stake was Vanguard Total Stock Market ETF: 1,038,550 shares worth $278M.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 45% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was ASML, an estimated $47.3M trimmed.
- Novo Holdings A/S's largest Q2 2024 buy was Vanguard Total Stock Market ETF: 1,038,550 shares worth $278M.
- Novo Holdings A/S added most to Kyverna Therapeutics in Q2 2024, an estimated $16M increase.
- Novo Holdings A/S's biggest Q2 2024 reduction was ASML, cutting an estimated $47.3M.
- Novo Holdings A/S fully exited Edgewell Personal Care in Q2 2024, selling an estimated $116M.
- Novo Holdings A/S's ten largest holdings make up 65% of its $1.85B portfolio in Q2 2024.
- Novo Holdings A/S opened 6 new positions and closed 3 in Q2 2024.
- Novo Holdings A/S's portfolio value rose 28% quarter-over-quarter to $1.85B.
Based on Novo Holdings A/S's 13F filing for Q2 2024, filed 14 Aug 2024.